Stanley Druckenmiller Duquesne Family Office
Stanley Druckenmiller is the founder of Duquesne Family Office and one of the most closely watched macro investors of his generation. He first became widely known as lead portfolio manager of the Quantum Fund alongside George Soros, including during the famous 1992 bet against the British pound. After returning outside capital, he has continued to invest with a flexible, top-down approach that blends macroeconomic views with concentrated equity and commodity positions.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$25.7M |
| 2 |
Gilead Sciences
GILD
|
+$21.3M |
| 3 |
Amgen
AMGN
|
+$20.7M |
| 4 |
Merck
MRK
|
+$19.4M |
| 5 |
Costco
COST
|
+$19.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$129M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$65.1M |
| 3 |
Meta Platforms (Facebook)
META
|
+$63.8M |
| 4 |
VanEck Gold Miners ETF
GDX
|
+$60M |
| 5 |
WBA
Walgreens Boots Alliance
WBA
|
+$38.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.25% |
| 2 | Consumer Discretionary | 16.43% |
| 3 | Communication Services | 12.04% |
| 4 | Materials | 7.93% |
| 5 | Consumer Staples | 4.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
YPF
YPF
$19.5B
| $11.1M | 1.36% |
+298,900
| New | +$10.5M |
|
27
State Street Health Care Select Sector SPDR ETF
XLV
$41.8B
| $11M | 1.35% |
172,300
| – | – |
|
28
Bath & Body Works
BBWI
$4.24B
| $10.1M | 1.24% |
+187,158
| New | +$9.41M |
|
29
State Street Financial Select Sector SPDR ETF
XLF
$58.5B
| $9.93M | 1.22% |
488,352
-14,581
| -3% | -$294K |
|
30
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
$46.5B
| $9.91M | 1.22% |
+58,300
| New | +$9.87M |
|
|
JWN
31
DELISTED
Nordstrom
JWN
| $9.79M | 1.2% |
+143,200
| New | +$9.86M |
|
|
FL
32
DELISTED
Foot Locker
FL
| $9.76M | 1.2% |
+175,400
| New | +$9.23M |
|
|
ARIA
33
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $8.88M | 1.09% |
+1,645,000
| New | +$9.61M |
|
|
LUMO
34
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $3.91M | 0.48% |
+20,278
| New | +$4.46M |
|
|
KITE
35
DELISTED
Kite Pharma, Inc.
KITE
| $1.14M | 0.14% |
+40,000
| New | +$990K |
|
36
Alibaba
BABA
$309B
| $889K | 0.11% |
+10,000
| New | +$898K |
|
37
American Airlines Group
AAL
$11B
| – | – |
-240,700
| Closed | -$10.3M |
|
38
ATI
ATI
$27.3B
| – | – |
-510,000
| Closed | -$23M |
|
39
AstraZeneca
AZN
$241B
| – | – |
-208,900
| Closed | -$15.5M |
|
40
Baidu
BIDU
$38.2B
| – | – |
-126,000
| Closed | -$23.5M |
|
41
Canadian Pacific Kansas City
CP
$79.7B
| – | – |
-460,000
| Closed | -$16.7M |
|
42
D.R. Horton
DHI
$42.1B
| – | – |
-494,429
| Closed | -$12.2M |
|
43
Devon Energy
DVN
$50.8B
| – | – |
-207,500
| Closed | -$16.5M |
|
44
EOG Resources
EOG
$76.4B
| – | – |
-288,200
| Closed | -$33.7M |
|
45
EQT Corp
EQT
$33B
| – | – |
-323,128
| Closed | -$18.8M |
|
46
Expeditors International
EXPD
$23.7B
| – | – |
-220,000
| Closed | -$9.71M |
|
47
Fluor
FLR
$7.2B
| – | – |
-192,800
| Closed | -$14.8M |
|
48
iShares China Large-Cap ETF
FXI
$4.33B
| – | – |
-281,100
| Closed | -$10.4M |
|
49
Halliburton
HAL
$27B
| – | – |
-368,700
| Closed | -$26.2M |
|
50
HCA Healthcare
HCA
$86.8B
| – | – |
-194,600
| Closed | -$11M |
|
Similar funds
Stanley Druckenmiller's Q3 2014 Portfolio in Review
As of Q3 2014, Stanley Druckenmiller held 69 positions worth $815M, down 42% from $1.4B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Stanley Druckenmiller withdrew a net $570M in Q3 2014, closing 33 positions and reducing 5 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $65.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 23% a quarter earlier, followed by Consumer Discretionary and Communication Services.
Against the trend, Stanley Druckenmiller opened a new position in Gilead Sciences worth $23.2M.
- Stanley Druckenmiller's largest Q3 2014 buy was Gilead Sciences: 217,500 shares worth $23.2M.
- Stanley Druckenmiller added most to Celgene Corp in Q3 2014, an estimated $25.7M increase.
- Stanley Druckenmiller's biggest Q3 2014 reduction was Alphabet (Google) Class C, cutting an estimated $129M.
- Stanley Druckenmiller fully exited Teva Pharmaceuticals in Q3 2014, selling an estimated $65.1M.
- Stanley Druckenmiller's ten largest holdings make up 57% of its $815M portfolio in Q3 2014.
- Stanley Druckenmiller opened 24 new positions and closed 33 in Q3 2014.
- Stanley Druckenmiller's portfolio value fell 42% quarter-over-quarter to $815M.
Based on Duquesne Family Office's 13F filing for Q3 2014, filed 14 Nov 2014.